Search results
Results from the WOW.Com Content Network
Pharmacological Research is a monthly peer-reviewed scientific journal covering pharmacology. It was established in 1969 as Pharmacological Research Communications, obtaining its current name in 1989. [1] [2] It is published by Elsevier and the editor-in-chief is Emilio Clementi (University of Milan).
Citing inadequacies with current practices in listing authors of papers in medical research journals, Drummond Rennie and co-authors, writing in the Journal of the American Medical Association (JAMA) in 1997, called for: a radical conceptual and systematic change, to reflect the realities of multiple authorship and to buttress accountability.
Still, omitting the authorship criteria by prioritizing hierarchy arguments, is an unethical practice. This kind of practices may hinder free-thinking and professional independence, and thus should be tackled by research managers, clear research guidelines and authors agreements.
The ICMJE recommendations (full title, "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals") are a set of guidelines produced by the International Committee of Medical Journal Editors for standardising the ethics, preparation and formatting of manuscripts submitted to biomedical journals for publication. [1]
EASE Guidelines summarize the most important editorial recommendations, aiming to make international scientific communication more efficient and to aid in preventing scientific misconduct. They also support the global initiative Healthcare Information For All by 2015 by advising authors to make abstracts of their papers highly informative ...
the authors disclose the existence of the preprint at submission (e.g. in the cover letter) once an article is published, the preprint should link to the published version (typically via DOI ) the preprint should not have been formally peer reviewed
GCP guidelines include standards on how clinical trials should be conducted, define the roles and responsibilities of institutional review boards, clinical research investigators, clinical trial sponsors, and monitors. In the pharmaceutical industry monitors are often called clinical research associates.
The aim of the PRISMA statement is to help authors improve the reporting of systematic reviews and meta-analyses. [3] PRISMA has mainly focused on systematic reviews and meta-analysis of randomized trials, but it can also be used as a basis for reporting reviews of other types of research (e.g., diagnostic studies, observational studies).